PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. [electronic resource]
Producer: 20151214Description: 4299-314 p. digitalISSN:- 1949-2553
- Adult
- Aged
- Aged, 80 and over
- Animals
- Antibiotics, Antineoplastic -- pharmacology
- Biomarkers, Tumor -- analysis
- Blotting, Western
- Breast Neoplasms -- drug therapy
- Doxorubicin -- pharmacology
- Drug Resistance, Neoplasm -- physiology
- Enzyme Activation -- physiology
- Female
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Mice
- Mice, Inbred BALB C
- Middle Aged
- Prognosis
- Protein Phosphatase 2 -- metabolism
- Real-Time Polymerase Chain Reaction
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.